Swaminathan Murugappan

1.7k total citations · 1 hit paper
27 papers, 1.3k citations indexed

About

Swaminathan Murugappan is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Swaminathan Murugappan has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Cardiology and Cardiovascular Medicine and 10 papers in Oncology. Recurrent topics in Swaminathan Murugappan's work include Platelet Disorders and Treatments (12 papers), Antiplatelet Therapy and Cardiovascular Diseases (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Swaminathan Murugappan is often cited by papers focused on Platelet Disorders and Treatments (12 papers), Antiplatelet Therapy and Cardiovascular Diseases (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Swaminathan Murugappan collaborates with scholars based in United States, United Kingdom and Australia. Swaminathan Murugappan's co-authors include Satya P. Kunapuli, Haripriya Shankar, Soochong Kim, Robert T. Dorsam, G. L. Prasad, Bryan N. Kahner, Anne Thomas, Marc Peeters, Timothy Price and Stefano Cascinu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Swaminathan Murugappan

26 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 339 citations Timothy Price, Marc Peeters et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Swaminathan Murugappan United States	15	458	382	351	336	204	27	1.3k
Roger van Kruchten Netherlands	14	581 1.3×	100 0.3×	325 0.9×	387 1.2×	211 1.0×	18	1.6k
Anna Garuti Italy	21	205 0.4×	477 1.2×	59 0.2×	644 1.9×	117 0.6×	67	1.5k
Jan Willem N. Akkerman Netherlands	18	520 1.1×	84 0.2×	280 0.8×	254 0.8×	158 0.8×	29	1.2k
A. Oda Japan	18	600 1.3×	134 0.4×	188 0.5×	484 1.4×	211 1.0×	32	1.4k
Mirko Doni Italy	19	209 0.5×	445 1.2×	137 0.4×	1.2k 3.5×	73 0.4×	29	1.7k
Gertie Gorter Netherlands	23	437 1.0×	54 0.1×	415 1.2×	412 1.2×	140 0.7×	51	1.3k
Keith Abe United States	14	291 0.6×	197 0.5×	74 0.2×	354 1.1×	123 0.6×	16	997
George Lam United States	15	239 0.5×	159 0.4×	75 0.2×	639 1.9×	63 0.3×	22	1.0k
Marilyne Lebret France	14	173 0.4×	93 0.2×	151 0.4×	836 2.5×	66 0.3×	18	1.4k

Countries citing papers authored by Swaminathan Murugappan

Since Specialization

Citations

This map shows the geographic impact of Swaminathan Murugappan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swaminathan Murugappan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swaminathan Murugappan more than expected).

Fields of papers citing papers by Swaminathan Murugappan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swaminathan Murugappan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swaminathan Murugappan. The network helps show where Swaminathan Murugappan may publish in the future.

Co-authorship network of co-authors of Swaminathan Murugappan

This figure shows the co-authorship network connecting the top 25 collaborators of Swaminathan Murugappan. A scholar is included among the top collaborators of Swaminathan Murugappan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swaminathan Murugappan. Swaminathan Murugappan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dumbrava, Ecaterina E., Syma Iqbal, Gregory P. Botta, et al.. (2025). A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors.. Journal of Clinical Oncology. 43(4_suppl). 828–828.

Ulahannan, Susanna V., Thomas U. Marron, Haeseong Park, et al.. (2024). Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 2524–2524. 2 indexed citations

Flinn, Ian W., William G. Wierda, Steven Coutré, et al.. (2019). ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 37(15_suppl). TPS7566–TPS7566. 6 indexed citations

Price, Timothy, Kathryn J. Newhall, Marc Peeters, et al.. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). e14623–e14623. 2 indexed citations

Price, Timothy, Marc Peeters, Tae Won Kim, et al.. (2015). Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology. 33(3_suppl). 705–705. 3 indexed citations

Price, Timothy, Marc Peeters, Tae Won Kim, et al.. (2015). Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). 3586–3586. 2 indexed citations

Price, Timothy, Marc Peeters, Tae Won Kim, et al.. (2014). Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology. 15(6). 569–579. 339 indexed citations breakdown →

Newhall, Kathryn J., Timothy Price, Marc Peeters, et al.. (2014). Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy. Annals of Oncology. 25. ii109–ii109. 17 indexed citations

Murugappan, Swaminathan, William Proctor Harris, Christopher G. Willett, & Edward H. Lin. (2013). Multidisciplinary Management of Locally Advanced Rectal Cancer: Neoadjuvant Approaches. Journal of the National Comprehensive Cancer Network. 11(5). 548–557. 4 indexed citations

10.

Getz, Todd M., Béla Nagy, Kamala Bhavaraju, et al.. (2009). Protein Kinase Cδ Differentially Regulates Platelet Functional Responses. Arteriosclerosis Thrombosis and Vascular Biology. 29(5). 699–705. 59 indexed citations

11.

Kim, Soochong, et al.. (2009). Lyn, PKC-δ, SHIP-1 interactions regulate GPVI-mediated platelet-dense granule secretion. Blood. 114(14). 3056–3063. 50 indexed citations

12.

Garcia, Analia, Haripriya Shankar, Swaminathan Murugappan, Soochong Kim, & Satya P. Kunapuli. (2007). Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochemical Journal. 404(2). 299–308. 76 indexed citations

13.

Kahner, Bryan N., et al.. (2006). Nucleotide receptor signaling in platelets. Journal of Thrombosis and Haemostasis. 4(11). 2317–2326. 158 indexed citations

14.

Murugappan, Swaminathan. (2006). The role of ADP receptors in platelet function. Frontiers in bioscience. 11(1). 1977–1977. 140 indexed citations

15.

Murugappan, Swaminathan, Florin Tuluc, Robert T. Dorsam, Haripriya Shankar, & Satya P. Kunapuli. (2004). Differential Role of Protein Kinase Cδ Isoform in Agonist-induced Dense Granule Secretion in Human Platelets. Journal of Biological Chemistry. 279(4). 2360–2367. 86 indexed citations

16.

Quinton, Todd M., et al.. (2004). Different G protein‐coupled signaling pathways are involved in α granule release from human platelets. Journal of Thrombosis and Haemostasis. 2(6). 978–984. 47 indexed citations

17.

Murugappan, Swaminathan, Haripriya Shankar, & Satya P. Kunapuli. (2004). Platelet Receptors for Adenine Nucleotides and Thromboxane A₂. Seminars in Thrombosis and Hemostasis. 30(4). 411–418. 56 indexed citations

18.

Shankar, Haripriya, Swaminathan Murugappan, Soochong Kim, et al.. (2004). Role of G protein–gated inwardly rectifying potassium channels in P2Y12 receptor–mediated platelet functional responses. Blood. 104(5). 1335–1343. 54 indexed citations

19.

Kunapuli, Satya P., Zhongren Ding, Robert T. Dorsam, et al.. (2003). ADP Receptors-Targets for Developing Antithrombotic Agents. Current Pharmaceutical Design. 9(28). 2303–2316. 72 indexed citations

20.

Dorsam, Robert T., Swaminathan Murugappan, Zhongren Ding, & Satya P. Kunapuli. (2003). Clopidogrel: Interactions with the P2Y₁₂Receptor and Clinical Relevance. Hematology. 8(6). 359–365. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact